7 Top Gainers In Healthcare Sector (KTOV, TYME, CRMD...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Kitov Pharma Ltd (KTOV)

Gained 169.23% to close Tuesday's (Jan.15) trading at $2.80.

News: The Company announced new data which demonstrate NT219's unique mechanism of action and anti-cancer effect. NT219 is in pre-clinical testing.

According to the Company, data show that even a short exposure of cancerous cells to NT219 was sufficient to trigger irreversible shutdown of cancer pathways, resulting in a long-term anti-cancer effect.

2. Tyme Technologies Inc. (TYME)

Gained 46.34% to close Wednesday's trading at $3.60.

News: The Company announced that it will hold a conference call with analysts and investors at 9 AM EST (6 AM PST) on January 18, to discuss the SM-88 preliminary Phase II pancreatic cancer data scheduled to be presented in four posters at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) being held later this week.

3. Checkpoint Therapeutics, Inc. (CKPT)

Gained 25.32% to close Tuesday's trading at $3.96.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase I/II clinical trial of CK-101 for the treatment of patients with EGFR mutation-positive non-small cell lung cancer is ongoing. The Company presented positive preliminary safety and efficacy data from this trial last September. -- A phase I trial of CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers is underway. Early this month, the Company expanded the CK-301 trial to include endometrial and colorectal cancer patients. The interim safety and efficacy data from this ongoing clinical trial is expected to be presented in the coming months.

4. CHF Solutions Inc. (CHFS)

CHF Solutions is a medical device company focused on commercializing Aquadex FlexFlow system for aquapheresis therapy.

Aquadex FlexFlow system is indicated for ultrafiltration to reduce fluid overload in patients when diuretics fail. The device is FDA 510(k) market cleared and CE marked.

Gained 23.26% to close Tuesday's trading at $11.18.

News: No news

Recent event:

On November 6, 2018, the Company reported third quarter financial results for the period ended September 30, 2018. Net sales rose to $1.36 million in the recent third quarter from $0.96 million in the comparable year-ago quarter.

5. Achieve Life Sciences Inc. (ACHV)

Achieve Life Sciences is a clinical-stage pharmaceutical company developing Cytisinicline for smoking cessation.

Gained 22.41% to close Tuesday's trading at $2.88.

News: No news

Clinical Trial & Near-term Catalyst:

-- A phase IIb optimization trial evaluating various dosing schedules of Cytisinicline, dubbed ORCA-1, is underway. The trial is enrolling 250 smokers at eight trial locations throughout the United States.

ORCA-1 trial results are expected in mid-2019.

6. MYnd Analytics Inc. (MYND)

MYnd is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients.

Gained 16.36% to close Tuesday's trading at $1.28.

News: No news

Recent event:

On January 7, the Company announced that it has entered into a definitive stock-for-stock merger agreement with Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment.

Emmaus is a commercial stage biopharmaceutical company, and its lead FDA-approved product is Endari, which is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Following the merger, Emmaus will become a wholly owned subsidiary of MYnd Analytics in exchange for MYnd Analytics' issuance of common stock to Emmaus shareholders and other equity holder. The surviving company will change its name to Emmaus and receive a new ticker symbol to reflect the name change.

7. CorMedix Inc. (CRMD)

Gained 15.95% to close Tuesday's trading at $1.89.

News: No news

Clinical Trial & Near-term Catalyst:

The lead product candidate Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, is under phase III development for patients undergoing chronic hemodialysis.

The phase III trial of Neutrolin, dubbed LOCK-IT-100, demonstrated efficacy last July. A meeting with the FDA to discuss Neutrolin's development path is expected this quarter (Q1, 2019).